{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T14:07:11Z","timestamp":1779199631276,"version":"3.51.4"},"reference-count":65,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2018,9,1]]},"DOI":"10.1001\/jamacardio.2018.2090","type":"journal-article","created":{"date-parts":[[2018,7,25]],"date-time":"2018-07-25T16:31:24Z","timestamp":1532536284000},"page":"883","source":"Crossref","is-referenced-by-count":17,"title":["Obesity-Associated Heart Failure as a Theoretical Target for Treatment With Mineralocorticoid Receptor Antagonists"],"prefix":"10.1001","volume":"3","author":[{"given":"Milton","family":"Packer","sequence":"first","affiliation":[{"name":"Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"2","key":"hrv180005r1","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.mce.2011.06.038","article-title":"Aldosterone, mineralocorticoid receptor, and heart failure.","volume":"350","author":"Messaoudi","year":"2012","journal-title":"Mol Cell Endocrinol"},{"issue":"5","key":"hrv180005r2","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrneph.2010.30","article-title":"Aldosterone: effects on the kidney and cardiovascular system.","volume":"6","author":"Briet","year":"2010","journal-title":"Nat Rev Nephrol"},{"issue":"9","key":"hrv180005r3","doi-asserted-by":"publisher","first-page":"597","DOI":"10.2459\/JCM.0000000000000102","article-title":"The effect of aldosterone-antagonist therapy on aortic elastic properties in patients with nonischemic dilated cardiomyopathy.","volume":"16","author":"Vizzardi","year":"2015","journal-title":"J Cardiovasc Med (Hagerstown)"},{"issue":"1","key":"hrv180005r4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3109\/10641963.2011.618200","article-title":"Serum aldosterone is associated with inflammation and aortic stiffness in normotensive overweight and obese young adults.","volume":"34","author":"Cooper","year":"2012","journal-title":"Clin Exp Hypertens"},{"issue":"2","key":"hrv180005r5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1515\/hmbci-2013-0025","article-title":"Obesity and cardiovascular disease: role of adipose tissue, inflammation, and the renin-angiotensin-aldosterone system.","volume":"15","author":"Lastra","year":"2013","journal-title":"Horm Mol Biol Clin Investig"},{"issue":"10","key":"hrv180005r6","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure.","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"issue":"14","key":"hrv180005r7","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"hrv180005r8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms.","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"issue":"15","key":"hrv180005r9","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction.","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"hrv180005r10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"issue":"17","key":"hrv180005r11","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1056\/NEJMc1612601","article-title":"Spironolactone metabolites in TOPCAT: new insights into regional variation.","volume":"376","author":"de Denus","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"hrv180005r12","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00392-015-0939-8","article-title":"General practitioners\u2019 adherence to chronic heart failure guidelines regarding medication: the GP-HF study.","volume":"105","author":"Hirt","year":"2016","journal-title":"Clin Res Cardiol"},{"issue":"3","key":"hrv180005r13","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1365-2753.2010.01455.x","article-title":"Current treatment of chronic heart failure in primary care; still room for improvement.","volume":"16","author":"Bosch","year":"2010","journal-title":"J Eval Clin Pract"},{"issue":"6","key":"hrv180005r14","first-page":"683","article-title":"Are the heart failure guidelines being implemented in primary care?","volume":"28","author":"Moscavitch","year":"2009","journal-title":"Rev Port Cardiol"},{"issue":"15","key":"hrv180005r15","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1001\/jama.2009.1493","article-title":"Use of aldosterone antagonists in heart failure.","volume":"302","author":"Albert","year":"2009","journal-title":"JAMA"},{"issue":"1","key":"hrv180005r16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1161\/CIRCULATIONAHA.104.527549","article-title":"Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001.","volume":"112","author":"Masoudi","year":"2005","journal-title":"Circulation"},{"issue":"1","key":"hrv180005r17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jacc.2012.08.1019","article-title":"Temporal trends and predictors in the use of aldosterone antagonists post-acute myocardial infarction.","volume":"61","author":"Rassi","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"hrv180005r18","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.ahj.2013.03.007","article-title":"Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure.","volume":"165","author":"Curtis","year":"2013","journal-title":"Am Heart J"},{"issue":"12","key":"hrv180005r19","doi-asserted-by":"publisher","first-page":"e002268","DOI":"10.1161\/JAHA.115.002268","article-title":"Temporal trends and hospital variation in mineralocorticoid receptor antagonist use in veterans discharged with heart failure.","volume":"4","author":"Dev","year":"2015","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"hrv180005r20","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.cardfail.2014.01.017","article-title":"Utilization pattern of mineralocorticoid receptor antagonists in contemporary patients hospitalized with acute decompensated heart failure: a single-center experience.","volume":"20","author":"Chamsi-Pasha","year":"2014","journal-title":"J Card Fail"},{"issue":"3","key":"hrv180005r21","doi-asserted-by":"publisher","first-page":"e002493","DOI":"10.1161\/JAHA.115.002493","article-title":"Barriers to adoption of mineralocorticoid receptor antagonists in patients with heart failure: a mixed-methods study.","volume":"5","author":"Dev","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"hrv180005r22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1161\/CIRCHEARTFAILURE.113.000709","article-title":"Guideline concordance of testing for hyperkalemia and kidney dysfunction during initiation of mineralocorticoid receptor antagonist therapy in patients with heart failure.","volume":"7","author":"Allen","year":"2014","journal-title":"Circ Heart Fail"},{"issue":"1","key":"hrv180005r23","doi-asserted-by":"publisher","first-page":"F7","DOI":"10.1530\/JME-16-0025","article-title":"Adipocytes, aldosterone and obesity-related hypertension.","volume":"57","author":"Dinh Cat","year":"2016","journal-title":"J Mol Endocrinol"},{"issue":"9","key":"hrv180005r24","doi-asserted-by":"publisher","first-page":"R1065","DOI":"10.1152\/ajpregu.00133.2015","article-title":"Reviving the use of aldosterone inhibitors in treating hypertension in obesity.","volume":"309","author":"Huby","year":"2015","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"11","key":"hrv180005r25","doi-asserted-by":"publisher","first-page":"4472","DOI":"10.1210\/jc.2007-1088","article-title":"Body mass index predicts aldosterone production in normotensive adults on a high-salt diet.","volume":"92","author":"Bentley-Lewis","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"hrv180005r26","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/j.1550-8528.1999.tb00418.x","article-title":"Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women.","volume":"7","author":"Goodfriend","year":"1999","journal-title":"Obes Res"},{"issue":"15","key":"hrv180005r27","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1161\/CIRCULATIONAHA.117.032474","article-title":"Leptin-aldosterone-neprilysin axis: identification of its distinctive role in the pathogenesis of the three phenotypes of heart failure in people with obesity.","volume":"137","author":"Packer","year":"2018","journal-title":"Circulation"},{"issue":"5","key":"hrv180005r28","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1161\/HYPERTENSIONAHA.115.06736","article-title":"Leptin mediates high-fat diet sensitization of angiotensin II-elicited hypertension by upregulating the brain renin-angiotensin system and inflammation.","volume":"67","author":"Xue","year":"2016","journal-title":"Hypertension"},{"issue":"22","key":"hrv180005r29","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1161\/CIRCULATIONAHA.115.018226","article-title":"Adipocyte-derived hormone leptin is a direct regulator of aldosterone secretion, which promotes endothelial dysfunction and cardiac fibrosis.","volume":"132","author":"Huby","year":"2015","journal-title":"Circulation"},{"issue":"1","key":"hrv180005r30","doi-asserted-by":"publisher","first-page":"F7","DOI":"10.1530\/JOE-16-0160","article-title":"Obesity, hypertension and aldosterone: is leptin the link?","volume":"230","author":"Xie","year":"2016","journal-title":"J Endocrinol"},{"issue":"5","key":"hrv180005r31","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1161\/HYPERTENSIONAHA.111.190223","article-title":"Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction.","volume":"59","author":"Briones","year":"2012","journal-title":"Hypertension"},{"issue":"3","key":"hrv180005r32","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1161\/HYPERTENSIONAHA.110.168872","article-title":"Adipocyte-derived factors regulate vascular smooth muscle cells through mineralocorticoid and glucocorticoid receptors.","volume":"58","author":"Nguyen Dinh Cat","year":"2011","journal-title":"Hypertension"},{"issue":"24","key":"hrv180005r33","doi-asserted-by":"publisher","first-page":"14211","DOI":"10.1073\/pnas.2336140100","article-title":"Human adipocytes secrete mineralocorticoid-releasing factors.","volume":"100","author":"Ehrhart-Bornstein","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"hrv180005r34","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1161\/01.HYP.0000154361.47683.d3","article-title":"Weight loss and the renin-angiotensin-aldosterone system.","volume":"45","author":"Engeli","year":"2005","journal-title":"Hypertension"},{"issue":"2","key":"hrv180005r35","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.numecd.2008.06.001","article-title":"Effect of weight loss through laparoscopic gastric banding on blood pressure, plasma renin activity and aldosterone levels in morbid obesity.","volume":"19","author":"Dall\u2019Asta","year":"2009","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"9","key":"hrv180005r36","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1096\/fj.06-7970com","article-title":"Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis.","volume":"21","author":"Caprio","year":"2007","journal-title":"FASEB J"},{"issue":"7","key":"hrv180005r37","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1055\/s-2005-870240","article-title":"Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes.","volume":"37","author":"Kraus","year":"2005","journal-title":"Horm Metab Res"},{"issue":"2","key":"hrv180005r38","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.bbrc.2012.01.139","article-title":"Contribution of glucocorticoid-mineralocorticoid receptor pathway on the obesity-related adipocyte dysfunction.","volume":"419","author":"Hirata","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"hrv180005r39","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","article-title":"Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction.","volume":"136","author":"Obokata","year":"2017","journal-title":"Circulation"},{"issue":"5","key":"hrv180005r40","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jacc.2016.05.043","article-title":"High-output heart failure: a 15-year experience.","volume":"68","author":"Reddy","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"hrv180005r41","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1161\/01.HYP.0000231338.41548.fc","article-title":"Plasma aldosterone is independently associated with the metabolic syndrome.","volume":"48","author":"Bochud","year":"2006","journal-title":"Hypertension"},{"issue":"5","key":"hrv180005r42","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1530\/EJE-10-1074","article-title":"Association of plasma aldosterone with the metabolic syndrome in two German populations.","volume":"164","author":"Hannemann","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"hrv180005r43","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","article-title":"Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction.","volume":"37","author":"Solomon","year":"2016","journal-title":"Eur Heart J"},{"issue":"5","key":"hrv180005r44","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1161\/01.CIR.0000112582.16683.EA","article-title":"Impact of obesity on plasma natriuretic peptide levels.","volume":"109","author":"Wang","year":"2004","journal-title":"Circulation"},{"issue":"5","key":"hrv180005r45","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1097\/HJH.0b013e3282f624a0","article-title":"Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans.","volume":"26","author":"Sarzani","year":"2008","journal-title":"J Hypertens"},{"issue":"7","key":"hrv180005r46","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.amjcard.2011.05.033","article-title":"Relation of visceral adiposity to circulating natriuretic peptides in ambulatory individuals.","volume":"108","author":"Cheng","year":"2011","journal-title":"Am J Cardiol"},{"issue":"8","key":"hrv180005r47","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1038\/ijo.2010.227","article-title":"Neprilysin, obesity and the metabolic syndrome.","volume":"35","author":"Standeven","year":"2011","journal-title":"Int J Obes (Lond)"},{"issue":"50","key":"hrv180005r48","doi-asserted-by":"publisher","first-page":"48066","DOI":"10.1074\/jbc.M204058200","article-title":"Human adipose tissue cells keep tight control on the angiotensin II levels in their vicinity.","volume":"277","author":"Schling","year":"2002","journal-title":"J Biol Chem"},{"issue":"5","key":"hrv180005r49","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1161\/01.HYP.0000244543.91937.79","article-title":"Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study.","volume":"48","author":"Rice","year":"2006","journal-title":"Hypertension"},{"issue":"9","key":"hrv180005r50","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.cardfail.2014.06.357","article-title":"Genetic and nongenetic factors influencing pharmacokinetics of B-type natriuretic peptide.","volume":"20","author":"Lanfear","year":"2014","journal-title":"J Card Fail"},{"issue":"4","key":"hrv180005r51","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1373\/clinchem.2005.062562","article-title":"B-type natriuretic peptide (BNP) and N-terminal pro-BNP in obese patients without heart failure: relationship to body mass index and gastric bypass surgery.","volume":"52","author":"St Peter","year":"2006","journal-title":"Clin Chem"},{"issue":"7","key":"hrv180005r52","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1007\/s00464-010-1565-1","article-title":"B-type natriuretic peptide increases after gastric bypass surgery and correlates with weight loss.","volume":"25","author":"Changchien","year":"2011","journal-title":"Surg Endosc"},{"issue":"5","key":"hrv180005r53","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3109\/10641963.2014.987391","article-title":"Comparison of aldosterone synthesis in adrenal cells, effect of various AT1 receptor blockers with or without atrial natriuretic peptide.","volume":"37","author":"Miura","year":"2015","journal-title":"Clin Exp Hypertens"},{"issue":"5","key":"hrv180005r54","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1111\/j.1523-1755.2005.00269.x","article-title":"Natriuretic and antialdosterone actions of chronic oral NEP inhibition during progressive congestive heart failure.","volume":"67","author":"Martin","year":"2005","journal-title":"Kidney Int"},{"issue":"8","key":"hrv180005r55","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.jash.2014.04.008","article-title":"Accumulation of microvascular target organ damage in newly diagnosed hypertensive patients.","volume":"8","author":"Triantafyllou","year":"2014","journal-title":"J Am Soc Hypertens"},{"issue":"8","key":"hrv180005r56","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nrneph.2013.110","article-title":"Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis.","volume":"9","author":"Brown","year":"2013","journal-title":"Nat Rev Nephrol"},{"issue":"9","key":"hrv180005r57","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1002\/ejhf.2017.19.issue-9","article-title":"Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity: insight from the EMPHASIS-HF trial.","volume":"19","author":"Olivier","year":"2017","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"hrv180005r58","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1161\/CIRCHEARTFAILURE.111.962654","article-title":"Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.","volume":"4","author":"Anand","year":"2011","journal-title":"Circ Heart Fail"},{"issue":"4","key":"hrv180005r59","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jchf.2016.11.015","article-title":"Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial.","volume":"5","author":"Anand","year":"2017","journal-title":"JACC Heart Fail"},{"issue":"11","key":"hrv180005r60","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.cardfail.2012.09.005","article-title":"Obesity and the response to intensified diuretic treatment in decompensated heart failure: a DOSE trial substudy.","volume":"18","author":"Gupta","year":"2012","journal-title":"J Card Fail"},{"issue":"1","key":"hrv180005r61","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1136\/hrt.57.1.17","article-title":"Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics.","volume":"57","author":"Bayliss","year":"1987","journal-title":"Br Heart J"},{"issue":"3","key":"hrv180005r62","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.ahj.2014.12.009","article-title":"A reappraisal of loop diuretic choice in heart failure patients.","volume":"169","author":"Buggey","year":"2015","journal-title":"Am Heart J"},{"issue":"6","key":"hrv180005r63","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/j.jacc.2004.04.059","article-title":"Furosemide and the progression of left ventricular dysfunction in experimental heart failure.","volume":"44","author":"McCurley","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"hrv180005r64","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1093\/cvr\/cvx097","article-title":"The role of mineralocorticoid receptor signaling in the cross-talk between adipose tissue and the vascular wall.","volume":"113","author":"Jia","year":"2017","journal-title":"Cardiovasc Res"},{"issue":"3","key":"hrv180005r65","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11906-016-0626-9","article-title":"Aldosterone production and signaling dysregulation in obesity.","volume":"18","author":"Vecchiola","year":"2016","journal-title":"Curr Hypertens Rep"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2689024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T16:52:42Z","timestamp":1720457562000},"score":1,"resource":{"primary":{"URL":"http:\/\/cardiology.jamanetwork.com\/article.aspx?doi=10.1001\/jamacardio.2018.2090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,1]]},"references-count":65,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2018.2090","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9,1]]}}}